Current options for the treatment of Helicobacter pylori

Bibliography

• Moayyedi P, Hunt RH. Helicobacter pylori public health implications. Helicobacter 2004;9(Suppl 1):67-72
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009;374:1449-61
   PubMed Web of Science ®Google Scholar
• Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241
   PubMedGoogle Scholar
• Georgopoulos SD, Polymeros D, Triantafyllou K, Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 2006;74:42-6
   Google Scholar
• Banic M, Franceschi F, Babic Z, Extragastric manifestations of helicobacter pylori infection. Helicobacter 2012;17(Suppl 1):49-55
   Google Scholar
• Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997;41:8-13
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O'Morain C, Current concepts in the management of helicobacter pylori infection–the maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64
   PubMed Web of Science ®Google Scholar
• Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Ladas SD, Karatapanis S, Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig Dis Sci 2000;45:63-7
   PubMed Web of Science ®Google Scholar
• Kamada T, Haruma K, Komoto K, Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999;4:204-10
   PubMed Web of Science ®Google Scholar
• Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol 2010;6:29-41
   PubMed Web of Science ®Google Scholar
• Lind T, Veldhuyzen van Zanten S, Unge P, Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138-44
   PubMedGoogle Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier JC, Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13
   PubMed Web of Science ®Google Scholar
• Vakil N, Lanza F, Schwartz H, Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107
   PubMed Web of Science ®Google Scholar
• Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31
   PubMed Web of Science ®Google Scholar
• Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62(1):34-42
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011;16:343-5
   PubMed Web of Science ®Google Scholar
• Fuccio L, Minardi ME, Zagari RM, Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62
   PubMed Web of Science ®Google Scholar
• Vallve M, Vergara M, Gisbert JP, Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16:1149-56
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29:720-30
   PubMed Web of Science ®Google Scholar
• Rokkas T, Sechopoulos P, Robotis I, Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy. Gastroenterol Res Pract 2012;2012:757926
   PubMed Web of Science ®Google Scholar
• Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82
   PubMed Web of Science ®Google Scholar
• Luther J, Higgins PD, Schoenfeld PS, Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73
   PubMed Web of Science ®Google Scholar
• Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14:5385-402
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Ladas SD, Karatapanis S, Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002;16:569-75
   PubMed Web of Science ®Google Scholar
• Michopoulos S, Tsibouris P, Bouzakis H, Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000;14:737-44
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Archavlis E, Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14:1237-43
   Google Scholar
• Garcia N, Calvet X, Gene E, Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol 2000;12:1315-18
   PubMedGoogle Scholar
• Perri F, Festa V, Merla A, Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002;7:99-104
   Google Scholar
• de Boer WA, van Etten RJ, Schneeberger PM, A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am J Gastroenterol 2000;95:641-5
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7
   PubMed Web of Science ®Google Scholar
• Saleem A, Qasim A, O'Connor HJ, Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther 2009;7:793-9
   PubMedGoogle Scholar
• Gisbert JP, Calvet X, O'Connor A, Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Leandro G, Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-3079; quiz 1080
   PubMed Web of Science ®Google Scholar
• Tong JL, Ran ZH, Shen J, Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41-53
   PubMed Web of Science ®Google Scholar
• Zullo A, De Francesco V, Hassan C, The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7
   PubMed Web of Science ®Google Scholar
• Vaira D, Zullo A, Vakil N, Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63
   PubMed Web of Science ®Google Scholar
• Wu DC, Hsu PI, Wu JY, Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41; e31
   PubMed Web of Science ®Google Scholar
• Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003;51:9-11
   PubMed Web of Science ®Google Scholar
• Luther J, Chey WD. Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort? Gastroenterology 2009;136:720-2
   PubMedGoogle Scholar
• Fakheri H, Taghvaei T, Hosseini V, A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012;17:43-8
   PubMed Web of Science ®Google Scholar
• Park HG, Jung MK, Jung JT, Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 2012;35:56-65
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Anderson GL, Morgan DR, 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-17
   PubMed Web of Science ®Google Scholar
• Treiber G, Ammon S, Schneider E, Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-8
   PubMed Web of Science ®Google Scholar
• Okada M, Oki K, Shirotani T, A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998;33:640-5
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34
   PubMedGoogle Scholar
• Georgopoulos S, Papastergiou V, Xirouchakis E, Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-Line H. Pylori eradication: a randomized trial. J Clin Gastroenterol 2012. [Epub ahead of print]
   Google Scholar
• Kim SY, Lee SW, Hyun JJ, Comparative study of helicobacter pylori eradication rates with 5-day quadruple “concomitant” therapy and 7-day standard triple therapy. J Clin Gastroenterol 2012;47:21-4
   Google Scholar
• Nagahara A, Miwa H, Ogawa K, Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5:88-93
   PubMed Web of Science ®Google Scholar
• Nagahara A, Miwa H, Yamada T, Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:417-21
   PubMedGoogle Scholar
• Neville PM, Everett S, Langworthy H, The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501
   PubMedGoogle Scholar
• Essa AS, Kramer JR, Graham DY, Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18
   PubMed Web of Science ®Google Scholar
• Kongchayanun C, Vilaichone RK, Pornthisarn B, Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012;17:282-5
   PubMed Web of Science ®Google Scholar
• Boyanova L, Mentis A, Gubina M, The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002;8:388-96
   PubMed Web of Science ®Google Scholar
• Georgopoulos S, Papastergiou V, Xirouchakis E, Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012;17:49-53
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012;17:269-76
   PubMed Web of Science ®Google Scholar
• Hsu PI, Wu DC, Wu JY, Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45
   PubMed Web of Science ®Google Scholar
• Hsu PI, Wu DC, Wu JY, Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011;16:146-52
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Romano M, Fernandez-Bermejo M, 14-day, high-dose acid suppression, non-bismuth quadruple therapies ("hybrid" vs. "concomitant") for Helicobacter pylori infection: a randomized trial. Gut 2012;61(Suppl 3):A47
   Google Scholar
• Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 2011;4:103-14
   Google Scholar
• Romano M, Cuomo A, Gravina AG, Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70
   PubMed Web of Science ®Google Scholar
• Zullo A, De Francesco V, Hassan C, Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis 2013;45(1):18-22
   Google Scholar
• Federico A, Nardone G, Gravina AG, Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143:55-61 e51; quize e13-54
   PubMed Web of Science ®Google Scholar
• Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract 2012;2012:974594
   PubMedGoogle Scholar
• Lee BH, Kim N, Hwang TJ, Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gisbert JL, Marcos S, Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-16
   PubMed Web of Science ®Google Scholar
• Kuo CH, Hsu PI, Kuo FC, Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother 2013;68(1):222-8
   PubMed Web of Science ®Google Scholar
• Gomollon F, Valdeperez J, Garuz R, [Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care]. Med Clin (Barc) 2000;115:1-6
   PubMedGoogle Scholar
• Marko D, Calvet X, Ducons J, Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005;10:22-32
   PubMed Web of Science ®Google Scholar
• Lee SK, Lee SW, Park JY, Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter 2011;16:410-14
   Google Scholar
• Karatapanis S, Skorda L, Georgopoulos S, Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection. Ann Gastroenterol 2009;22:263-7
   Google Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Perez-Aisa A, Bermejo F, Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a spanish multicenter study of 1000 patients. J Clin Gastroenterol 2012
   Web of Science ®Google Scholar
• Manfredi M, Bizzarri B, de'Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012;17:246-53
   PubMed Web of Science ®Google Scholar
• Kuo CH, Hu HM, Kuo FC, Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24
   PubMed Web of Science ®Google Scholar
• Wong WM, Gu Q, Chu KM, Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7
   Google Scholar
• Di Caro S, Franceschi F, Mariani A, Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480-5
   Google Scholar
• Chuah SK, Tai WC, Hsu PI, The Efficacy of second-line anti-helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment - a pilot study. Helicobacter 2012;17:374-81
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, Rassu M, In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000;95:833-4
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012;35:209-21
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012;35:941-7
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Perez-Aisa A, Castro-Fernandez M, Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 2010;42:287-90
   PubMedGoogle Scholar
• Peitz U, Sulliga M, Wolle K, High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24
   PubMed Web of Science ®Google Scholar
• Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007;137:812S-8S
   PubMed Web of Science ®Google Scholar
• Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79
   PubMed Web of Science ®Google Scholar
• Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14:97-107
   PubMed Web of Science ®Google Scholar
• Wenzhen Y, Yumin L, Quanlin G, Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010;49:1103-9
   Google Scholar
• Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med 2011;50:2717; author reply 2719-2720
   Google Scholar
• Furuta T, Shirai N, Kodaira M, Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8
   PubMed Web of Science ®Google Scholar
• Rupnow MF, Chang AH, Shachter RD, Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009;200:1311-17
   PubMed Web of Science ®Google Scholar